Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients with Renal Insufficiency Compared with Gadodiamide

Investigative Radiology

Volumn 51, Issue 11, 2016, Pages 701-705

  Bruce, Richard ^a   Wentland, Andrew L ^b   Haemel, Anna K ^c   Garrett, Robert W ^d   Sadowski, Donna R ^e   Djamali, Arjang ^d   Sadowski, Elizabeth A ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Jr Hospital of Cook County   (United States)

Author keywords

gadobenate; gadodiamide; gadolinium based contrast agents; MR contrast agents; nephrogenic systemic fibrosis

Indexed keywords

GADOBENATE DIMEGLUMINE; GADODIAMIDE; CONTRAST MEDIUM; GADOBENIC ACID; GADOLINIUM PENTETATE; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ARTICLE; CONTRAST ENHANCEMENT; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; INCIDENCE; KIDNEY FAILURE; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; COMORBIDITY; COMPARATIVE STUDY; GLOMERULUS FILTRATION RATE; IMAGE ENHANCEMENT; NEPHROGENIC FIBROSING DERMOPATHY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RENAL INSUFFICIENCY; RISK ASSESSMENT; RISK FACTOR;

COMORBIDITY; CONTRAST MEDIA; GADOLINIUM DTPA; GLOMERULAR FILTRATION RATE; HUMANS; IMAGE ENHANCEMENT; INCIDENCE; MAGNETIC RESONANCE IMAGING; MEGLUMINE; NEPHROGENIC FIBROSING DERMOPATHY; ORGANOMETALLIC COMPOUNDS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84958780894     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000259     Document Type: Article

References (48)

1. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-1108.
2. Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol. 2008;66:191-199.
3. Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial. 2008;21:123-128.
4. Marckmann P, Skov L. Nephrogenic systemic fibrosis: clinical picture and treatment. Radiol Clin North Am. 2009;47:833-840.
5. Panesar M, Banerjee S, Barone GW. Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation. Clin Transplant. 2008;22:803-808.
6. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359-2362.
7. Khurana A, Greene JF Jr, HighWA. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. J Am Acad Dermatol. 2008;59:218-224.
8. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol. 2007;188:586-592.
9. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148-157.
10. Pryor JG, Scott GA. Nephrogenic systemic fibrosis: a clinicopathologic study of 6 cases. J Am Acad Dermatol. 2007;57:902-903.
11. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007;245:168-175.
12. Lauenstein TC, Salman K, Morreira R, et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging. 2007;26:1198-1203.
13. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology. 2008;248:799-806.
14. Wiginton CD, Kelly B, Oto A, et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. AJR Am J Roentgenol. 2008;190:1060-1068.
15. KallenAJ, JhungMA, Cheng S, et al. Gadolinium-containingmagnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis. 2008;51:966-975.
16. PrinceMR, Zhang H,MorrisM, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008;248:807-816.
17. Shabana WM, Cohan RH, Ellis JH, et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol. 2008;190:736-741.
18. Heinz-Peer G, Neruda A,Watschinger B, et al. Prevalence ofNSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease. Eur J Radiol. 2010;76:129-134.
19. Reilly RF. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol. 2008;3: 747-751.
20. Hope TA, Herfkens RJ, Denianke KS, et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine. Invest Radiol. 2009;44:135-139.
21. Janus N, Launay-Vacher V, Karie S, et al. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol. 2010;73:357-359.
22. Perez-Rodriguez J, Lai S, Ehst BD, et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment-report of 33 cases. Radiology. 2009;250:371-377.
23. FDA Web Site August 26, 2013. http://www.fda.gov/Drugs/DrugSafety/ucm223966.htm. Accessed December 2, 2015.
24. Daftari Besheli L, Aran S, Shaqdan K, et al. Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014;69:661-668.
25. Thomsen HS, Morcos SK, Almén T, et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR contrast medium safety committee guidelines. Eur Radiol. 2013;23:307-318.
26. Zou Z, Zhang HL, Roditi GH, et al. Nephrogenic systemic fibrosis: reviewof 370 biopsy-confirmed cases. JACC Cardiovasc Imaging. 2011;4:1206-1216.
27. Yang L, Krefting I, Gorovets A, et al. Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration. Radiology. 2012;265:248-253.
28. Penfield JG, Reilly RF. Gadolinium and nephrogenic systemic fibrosis: have we overreacted? Semin Dial. 2011;24:480-486.
29. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(suppl 1):S1-S266.
30. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003;15:785-790.
31. PrinceMR, Zhang HL, Roditi GH, et al. Risk factors for NSF: a literature review. J Magn Reson Imaging. 2009;30:1298-1308.
32. Altun E, Martin DR, Wertman R, et al. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy-report from two U.S. Universities. Radiology. 2009;253:689-696.
33. MartinDR, Krishnamoorthy SK, Kalb B, et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging. 2010;31:440-446.
34. Amet S, Launay-Vacher V, Clément O, et al. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study. Invest Radiol. 2014;49:109-115.
35. Sieber MA, Lengsfeld P, Frenzel T, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol. 2008;18:2164-2173.
36. Grant D, Johnsen H, Juelsrud A, et al. Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol. 2009;50:156-169.
37. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008;43:817-828.
38. Nandwana SB, Moreno CC, Osipow MT, et al. Gadobenate dimeglumine administration and nephrogenic systemic fibrosis: is there a real risk in patients with impaired renal function? Radiology. 2015;276:741-747.
39. Soulez G, Bloomgarden DC, Rofsky NM, et al. Prospective cohort study of nephrogenic systemic fibrosis in patients with stage 3-5 chronic kidney disease undergoing MRI with injected gadobenate dimeglumine or gadoteridol. AJR Am J Roentgenol. 2015;205:469-478.
40. Lauenstein T, Ramirez-Garrido F, Kim YH, et al. Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study. Invest Radiol. 2015;50:416-422.
41. Beckett KR,Moriarity AK, Langer JM. Safe use of contrast media: what the radiologist needs to know. Radiographics. 2015;35:1738-1750.
42. Abujudeh HH, Kaewlai R, Kagan A, et al. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology. 2009;253:81-89.
43. Prince MR, Zhang HL, Prowda JC, et al. Nephrogenic systemic fibrosis and its impact on abdominal imaging. Radiographics. 2009;29:1565-1573.
44. Altun E, Semelka RC, Cakit C. Nephrogenic systemic fibrosis and management of high-risk patients. Acad Radiol. 2009;16:897-905.
45. Thomsen HS, Marckmann P, Logager VB. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis? Acta Radiol. 2007;48:593-596.
46. Marckmann P, Skov L, Rossen K, et al. Case control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2007;22:3174-3178.
47. Smorodinsky E, AnsdellDS, FosterZW, et al. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents. J Magn Reson Imaging. 2015;41:1259-1267.
48. Elmholdt TR, Olesen AB, Jørgensen B, et al. Nephrogenic systemic fibrosis in Denmark-a nationwide investigation. PLoS One. 2014;9:e100407.